Hester Biosciences Limited has informed the Exchange that Board of Directors at its meeting held on May 09, 2025, recommended Final Dividend of Rs. 7 per equity share.
HESTERBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Hester Biosciences' Board approved audited standalone and consolidated financial results for Q4 and FY ended 31 March 2025, with statutory auditors issuing an unmodified opinion. The Board recommended a final dividend of Rs. 7 per equity share (70% on face value of Rs. 10), subject to shareholder approval. On a consolidated basis, revenue from operations grew modestly to Rs. 3,111.02 million (vs Rs. 3,045.46 million in FY24, up ~2.2%), while profit after tax jumped ~36% to Rs. 288.26 million (vs Rs. 211.66 million). Standalone revenue was nearly flat at Rs. 2,864.66 million, but standalone PAT rose ~17% to Rs. 318.42 million. The company also appointed Shah & Shah Associates as Secretarial Auditor for FY 2025-26 to FY 2029-30. Operating cash flow remained strong at Rs. 645.11 million on a consolidated basis.
Positive for shareholders — a healthy dividend payout, clean audit opinion, and strong consolidated profit growth signal stable operations, though standalone revenue growth was muted and ongoing capital expenditure on the BSL-3 facility continues to absorb cash.